Mr. Moorhead has over 20 years of experience in a variety of finance roles serving both public and private companies. For the last 10 years, Dan worked at Evolving Systems, Inc. (a Nasdaq listed company), most recently as Chief Financial Officer after having served as Vice President of Finance & Administration and Corporate Controller. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.
Thomas Sandgaard, CEO of Zynex stated, “I am very excited to welcome Dan Moorhead as Zynex’s Chief Financial Officer. Mr. Moorhead is a seasoned professional with a successful public company track record and has extensive experience with acquisitions of companies, both domestically and internationally. I believe Dan will be a great asset to the company. One of our long-term goals is to list on a larger exchange, such as Nasdaq or NYSE, and we believe the improvements we are making to the organization, including expanding our sales force and the more recent improvements to our billing and collection efforts, will position us well for up-listing. We continue to take advantage of the huge void in the electrotherapy industry and I am excited to soon be launching our Blood Volume Monitor into the hospital market for non-invasively detecting blood loss and internal bleeding.”
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our international expansion efforts, our ability to engage additional sales representatives and their success, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation, our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company’s website.
To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/zynex-hires-chief-financial-officer-300471475.html
Copyright (C) 2017 PR Newswire. All rights reserved